mRNA 1083
Alternative Names: COVID+Flu vaccine - Moderna Therapeutics; mRNA-1083; mRNA-1083.1; mRNA-1083.2; mRNA-1083.3Latest Information Update: 01 Aug 2024
At a glance
- Originator Moderna Therapeutics
- Class COVID-19 vaccines; Influenza virus vaccines; RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID 2019 infections; Influenza virus infections
Most Recent Events
- 15 Jul 2024 ModernaTX initiates a phase II trial in COVID-2019 infections (Prevention) in USA and Canada (IM) (NCT06508320)
- 15 Jul 2024 ModernaTX initiates a phase II trial in Influenza virus infections (Prevention) in USA and Canada (IM) (NCT06508320)
- 10 Jun 2024 Immunogenicity and adverse event data from a phase III trial in COVID-2019 infections released by Moderna Therapeutics